Back

Sanofi ADR

Ticker: SNY ISIN: US80105N1054
Add to portfolio Portfolio analysis in 2min
Stock Large-cap
Market cap
$116.71B
P/E
15.69
Forward P/E
9.78
Profit margin
19.84%
Revenue growth QoQ
-7.00%
Div. yield
0.00%
Beta
0.40
$45.69 -0.35%
Price as of 2026-08-24 · NASDAQ

Performance by timeframe

Rolling returns
1 Month +3.84%
6 Months +1.93%
1 Year -3.80%
5 Years +1.81% p.a.+9.37%
10 Years +5.89% p.a.+77.18%
Since inception +5.62% p.a.+274.81%
Calendar year returns
YTD -0.49%
2025 +4.93%
2024 +1.09%
2023 +6.71%
2022 +0.47%
2021 +7.00%

Key stats

Market cap
116.71B
P/E
15.69
Dividend yield
0.00%
Beta
0.40
52-week range
44.62 - 57.57
50-day MA
49.52
200-day MA
49.86
Section 1

Business overview

Company profile data from fundamentals.

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sector Healthcare
Industry Drug Manufacturers - General
Country France
Exchange NASDAQ
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 8.84%
ROA 4.61%
Profit margin 19.84%
Operating margin 28.73%
PEG ratio 0.73
Revenue/share TTM 18.66
Revenue TTM 45.93B
EBITDA 12.33B
Gross profit TTM 33.07B
Beta 0.40

Valuation

Trailing P/E 15.69
Forward P/E 9.78
P/B 1.36
P/S 2.54
EV/EBITDA 8.35
EV/Revenue 2.30
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 4.56
Quarterly earnings growth 2.40%
Revenue TTM 45.93B
Reported quarters 65
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 0.00%
Forward annual div. yield 4.56%
Dividend per share 0.0000
Payout ratio 51.46%
Ex-dividend date 2025-05-09
Split factor 5:1
Last split date 2013-09-30
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $58.68
Analyst rating 4.1818

Ownership & short interest

Shares outstanding 2.42B
Shares float 1.10B
Institutional ownership 9.89%
Insider ownership 0.10%
Short ratio 2.76
Short % of float 0.35%

Details

Instrument metadata and source update timestamps.

Symbol SNY
Name Sanofi ADR
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US80105N1054
Country USA
Code + exchange SNY.NASDAQ
Last price date 2026-01-06
Fundamentals updated 2026-01-07

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.